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The conventional C-strain vaccine induces early protection against classical swine fever (CSF), but infected animals
cannot be distinguished from vaccinated animals. The CP7_E2alf marker vaccine, a pestivirus chimera, could be a
suitable substitute for C-strain vaccine to control CSF outbreaks. In this study, single oral applications of CP7_E2alf
and C-strain vaccines were compared for their efficacy to induce protection against a CSF virus (CSFV) challenge
with the moderately virulent Bas-Rhin isolate, in pigs as early as two days post-immunization. This work emphasizes
the powerful potential of CP7_E2alf vaccine administered orally by a rapid onset of partial protection similar to that
induced by the C-strain vaccine. Furthermore, our results revealed that both vaccinations attenuated the effects
induced by CSFV on production of the pig major acute phase protein (PigMAP), IFN-α, IL-12, IL-10, and TGF-β1
cytokines. By this interference, several cytokines that may play a role in the pathogeny induced by moderately
virulent CSFV strains were revealed. New hypotheses concerning the role of each of these cytokines in CSFV
pathogeny are discussed. Our results also show that oral vaccination with either vaccine (CP7_E2alf or C-strain)
enhanced CSFV–specific IgG2 production, compared to infection alone. Interestingly, despite the similar antibody
profiles displayed by both vaccines post-challenge, the production of CSFV-specific IgG1 and neutralizing antibodies
without challenge was lower with CP7_E2alf vaccination than with C-strain vaccination, suggesting a slight
difference in the balance of adaptive immune responses between these vaccines.Introduction
Classical swine fever (CSF) is a highly contagious viral di-
sease in swine that leads to important economic losses
worldwide. The CSF virus (CSFV), a Pestivirus member of
the Flaviviridae family, is a small enveloped RNA virus en-
coding four structural proteins and eight non-structural
proteins. The E2 glycoprotein is the most immunogenic
CSFV protein. The severity of clinical signs varies accor-
ding to host parameters but is also dependent on the viru-
lence of the viral strains [1]. Highly virulent (HV) strains
cause an acute hemorrhagic form of the disease that
induces marked immune suppression and high mortality,* Correspondence: marie-frederique.lepotier@anses.fr
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reproduction in any medium, provided the orwhereas moderately virulent (MV) strains induce either a
sub-acute or a chronic form of the disease from which
pigs may recover.
Most countries in the European Union (EU) are CSF-
free, but the virus can periodically be reintroduced via wild
boars which may constitute a reservoir. Most of the re-
cently isolated European strains are MV strains belonging
to the 2.3 genotype. Since the 1990s, a non-vaccination
stamping-out policy has been enforced in the EU, leading
to pre-emptive culling in affected countries [2]. Despite
the availability and efficacy of the conventional C-strain
vaccine (an attenuated live strain of CSFV) in disease pre-
vention, vaccinated animals cannot be distinguished from
infected animals by serological diagnosis. In some EU
countries, the aim of oral vaccination campaigns is to
eradicate the virus in wild boar populations by using baitsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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duced by administration both by the intramuscular route
to domestic pigs and by oral route to wild boars would be
an asset for a new vaccine.
Live marker vaccines against CSFV, based on viral vec-
tors or chimeric pestiviruses, are the most promising op-
tion for rapid onset of protection, with both single dose
and oral application possibilities [5]. The modified vaccine
CP7_E2alf is a chimera of the bovine viral diarrhea virus
expressing the CSFV E2 protein. It displays promising po-
tency and induces similar effective protection against a
CSFV challenge to the C-strain [6]. The CP7_E2alf vaccine
behaves similarly to CSFV and uses the same primary rep-
lication site [7]. Moreover, the safety and efficiency of the
CP7_E2alf vaccine in both intramuscular and oral applica-
tion protocols has been demonstrated in pigs as well as
wild boars, together with persistent immunity for 6 months
post-vaccination [8-10]. The C-strain vaccine is able to in-
duce full clinical protection and partial protection against
an HV strain of CSFV 4 and 2 days post-vaccination, res-
pectively [11]. The C-strain vaccine can also induce
complete protection against a MV strain at 5 days post-
vaccination and partial protection after 3 days [12]. The
CP7_E2alf marker vaccine confers full clinical protection
against an HV strain challenge 7 days post-intramuscular
immunization or 14 days post-oral immunization [13].
Protection from the disease is mainly associated with
the humoral immune response but CSFV-neutralizing
antibodies usually appear about 2 weeks post-vaccination.
Thus, the early efficacy of the C-strain vaccine indicates
that other immune responses may also be involved, such
as cell-mediated immunity with significant IFN-γ produc-
tion in relation to protection [14]. CSFV infection is char-
acterized by the enhanced release of IFN-α and
proinflammatory cytokines, such as TNF-α, IL-6 and IL-1,
which disturb the homeostasis of the cellular environment
[15-17]. Conversely, vaccine combinations with human
IFN-α or porcine IL-6 improve immunity to CSFV in pigs
[18,19]. The respective role of cytokines in pathogeny or
protection remains to be determined.
In this study, we compared the capacities of a single
oral application of CP7_E2alf or C-strain vaccine to pro-
tect swine from a challenge with a MV CSFV field strain,
as early as 2 days post-oral vaccination. The powerful
potential of the CP7_E2alf marker vaccine as a substitute
for C-strain vaccine was demonstrated. Mainly, the in-
vestigation of immune responses against early challenge
by antibodies and cytokine profile-induced post-oral vac-
cination, suggested that the CP7_E2alf vaccine, like the
C-strain vaccine, interferes with the cytokine responses
induced by CSFV infection. Differences in adaptive im-
mune responses induced between the C-strain vaccine
and the CP7_E2alf vaccine were also suggested by anti-
body profiles.Materials and methods
Vaccines and virus
RIEMSERW Schweinepestvakzine baits (vaccine solution
from the blister of baits used for the wild boar oral vac-
cination campaign) were used for C-strain immunization
(Riemser Arzneimittel AG, Greifswald - Insel Riems,
Germany). The CP7_E2alf vaccine [6] was produced by
Pfizer (Pfizer Olot, La Vall de Bianya, Spain). The MV
Bas-Rhin strain (genotype 2.3) used for the CSFV chal-
lenge was isolated from a wild boar in France in 2003
and propagated for 3 passages on porcine kidney cell
line PK15.
Animal experiment design
Nine-week-old specific-pathogen-free Large White pigs
from our protected facilities were randomly assigned to
six groups of five animals housed in six separate rooms.
Two groups were orally vaccinated with a single protective
dose of either C-strain vaccine or CP7_E2alf vaccine (mini-
mum titre of 104.5 TCID50/dose for C-strain and 10
5.5
TCID50/dose for CP7_E2alf) and oro-nasally challenged
two days later with the Bas-Rhin strain (106 TCID50/pig).
Two other groups were vaccinated with either C-strain
vaccine or CP7_E2alf vaccine and one group was infected
with the Bas-Rhin strain. One group was neither vacci-
nated nor infected and served as the control. For oral vac-
cination, a solution of either C-strain vaccine or CP7_E2alf
vaccine was administered in the mouth using a 2 mL syr-
inge without a needle. For oro-nasal infection, 2 mL of the
Bas-Rhin viral solution was injected into each nostril and
1 mL was administered in the mouth using a 5 mL syringe
without a needle.
Rectal temperature, weight gain and clinical score were
monitored daily as previously described [20]. Blood sam-
ples were collected before vaccination (on day 0), at
5 days post-vaccination (dpv) (i.e. 3 days post-infection
(dpi) or challenge) and then 2 or 3 times per week until
27 dpv (i.e. 25 dpi).
The animal experiment protocol was approved by the
French national ethics committee ComEth Anses/ENVA/
UPEC.
Sample treatment
Blood lymphocyte counts were measured with a MS9
hematology analyzer (Melet Schloesing laboratoires, Osny,
France). Serum samples were purified from coagulated
blood samples by centrifugation at 3000 × g for 5 min.
Virological tests
RNA was purified from whole blood using the RNeasy
mini kit (Qiagen, Courtaboeuf, France). The CSFV gen-
ome was detected by performing real time RT-PCR (rRT-
PCR) using the commercial TaqVet CSF kit (LSI, Lissieu,
France) in which the primers are located in 5’NTR.
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vaccine was assessed by rRT-PCR as previously described
[21]. Virus titration from blood was performed on PK15
cells, according to the OIE’s manual of diagnostic tests [22].Serological tests
CSFV-specific IgG1 and IgG2 were measured in serum by
indirect ELISA. CSFV-infected cell extracts (Alfort 187
strain), prepared using a detergent solution containing 2%
Octyl b-D-glucopyranoside, were applied to Maxisorp
microplates (Nunc, Roskilde, Denmark), incubated over-
night at RT and blocked for 1 h at RT with 10% FBS-2%
milk-PBS. Thereafter, sera were incubated for 1 h at 37C
with either mouse anti-porcine IgG1 at 1:250 or IgG2 at
1:100 (AbD Serotec, Oxford, UK). For detection, rabbit
anti-mouse IgG HRP-conjugated secondary antibody was
added at 1:250 (DAKO, Glostrup, Denmark) for 30 min at
37C and peroxidase activity was measured using TMB
substrate (Sigma-Aldrich, St Louis, USA) at 450 nm.
CSFV-specific neutralizing antibodies (NAb) against the
Bas-Rhin strain were assayed using the virus neutralization
test on PK15 cells according to the OIE’s manual of diag-
nostic tests [22].Cytokine quantifications
Porcine cytokines were measured in serum using ELISA
kits from Invitrogen for IL-18, IL-10, IL-4, IFN-γ and
TNF-α (Life Technologies, Carlsbad, USA), from R&D
systems for IL-1β, TGF-β1, IL-6 and IL-12 (R&D sys-
tems, Minneapolis, USA) and from Kitvia for pig major
acute phase protein (pigMAP) (KitVia, Labarthe Inard,
France). Porcine IFN-α was detected using an ELISA
test, as previously described [17].
Porcine IL-10, IL-4 and IFN-γ gene expressions were
assessed in unpurified cells from whole blood using real
time RT-PCR performed using the SuperScript III Platinum
One-Step Quantitative RT-PCR System (Life Technologies,
Carlsbad, USA). β-actin was used as endogenous control to
normalize the quantification of target genes. Previously
published primers and probes were used for cytokines [23]
and β-actin [24]. The relative expressions of target genes
were calculated using the R = 2–ΔΔCT equation.Statistical tests
The measured variation for a treated group was com-
pared with that of the control group (statistical signifi-
cance indicated in the figures) or another treated group
and analyzed by Mann–Whitney test. Statistical tests
were performed using Systat 9 software (Systat Software
Inc., Point Richmond, USA), with the limit of significance
set at p < 0.05. The error bars on the graphs represent
the standard error (SE).Results
CP7_E2alf vaccine attenuates clinical expression of the
disease
Without challenge, neither oral vaccination induced any
(or very few) signs of disease (Figure 1). No characteristic
lesions were observed during necropsy, except for reactive
mesenteric or ileo-caecal lymph nodes in two pigs vacci-
nated with either the C-strain or CP7_E2alf. Interestingly,
a higher blood lymphocyte count was apparent at 12 dpv
in the group vaccinated with CP7_E2alf whereas transient
lymphocyte depletion was observed at 5 dpv in the group
vaccinated with C-strain (Figure 1d).
After challenge at 2 dpv, both oral vaccinations induced
partial clinical protection (Figure 1). With the CP7_E2alf
vaccination, the mean clinical score was significantly atte-
nuated to 1 at 5-7 dpi (p = 0.03) (Figure 1a), the decrease
in daily weight gain observed at 7 dpi was reduced,
(Figure 1b) and the duration of hyperthermia was shor-
tened to only one day (on 5 dpi) (Figure 1c). However, the
CP7_E2alf vaccine, unlike the C-strain vaccine, did not
prevent hyperthermia. No cyanosis was observed at ne-
cropsy with either vaccination whereas this typical skin le-
sion was observed in two infected pigs. Thymus atrophy
was observed in only one pig in each vaccinated group but
in three infected pigs. Moreover, the duration of lympho-
penia was shorter in both vaccinated groups (from 3 to 7
dpi) (Figure 1d), and significantly attenuated in compari-
son to the infected group between 5 and 14 dpi (p < 0.01).
Blood lymphocyte counts were increased in both vacci-
nated groups and attained higher levels than the control
group at 18 dpi (p < 0.05), whereas this was not observed
with the infection alone. In this experiment, only one pig
(No. 3906) in the infected group did not recover from the
disease and had to be euthanized prematurely at 21 dpi.
All vaccinated pigs had recovered by the second week
post-challenge, whereas two unvaccinated pigs still pre-
sented signs of disease.CP7_E2alf vaccine reduces viremia duration
Without challenge, the CP7_E2alf vaccine genome was
rarely detected by rRT-PCR in blood (one pig from 7 to
9 dpv and another at 5 dpv only) and the C-strain vac-
cine genome was detected in all pigs from 9 to 12 dpv
only (data not shown). After challenge at 2 dpv, virus
isolation was delayed in both vaccinated groups. No
CP7_E2alf vaccinated pig was positive, one C-strain vacci-
nated pig was positive whereas four unvaccinated pigs were
positive at 3 dpi (Table 1). Although the CSFV genome was
detected in all infected groups throughout the experiment,
it was not detected in one CP7_E2alf vaccinated pig or in
three C-strain vaccinated pigs at 25 dpi. In addition to this
slight reduction of the duration of viremia with both vac-
cines, a maximum mean titer of 103.0 TCID50/mL was
Figure 1 Clinical parameters monitored in experimental groups. (a) Clinical score, (b) Daily weight gain, (c) Rectal temperature and (d) Blood
lymphocyte count. All data are reported as the mean (± SE) of results obtained for the 5 pigs in each group. *p < 0.05 compared each
post-vaccination, post-challenge or post-infection value with the respective control value using the Mann–Whitney test. Dotted line with white
triangles: CP7_E2alf vaccinated group (CP7 vacc); dotted line with white squares: C-strain vaccinated group (C vacc); dotted line with white circles:
control group; full line with black triangles: CP7_E2alf vaccinated and challenged group (CP7 vacc & chal); full line with black squares: C-strain
vaccinated and challenged group (C vacc & chal); full line with black circles: infected group.
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104.1 TCID50/mL at 7 dpi in unvaccinated pigs.CP7_E2alf vaccine attenuates the modulations of cytokine
production related to CSFV infection
Without challenge, and compared to the control pigs, the
serum levels of PigMAP, TGF-β1 and IL-6 were not signifi-
cantly modified by either vaccination (Figure 2a, 2d, 2f).
No differences in IFN-α and TNF-α levels were observed
after vaccination with CP7_E2alf. In contrast, C-strain vac-
cination produced low levels of IFN-α at 5 dpv (Figure 2b)
and a slight increase in TNF-α at 5 dpv (Figure 2c).
Although the IL-12 levels induced by both vaccinations
were significantly higher than in the controls, the increase
occurred later and was smaller with CP7_E2alf vaccination
than with C-strain vaccination, with maximum values of
434 pg/mL at 12 dpv and 693 pg/mL at 5 dpv, respectively
(Figure 2e).After challenge at 2 dpv, the duration of high levels of
infection-induced PigMAP was reduced to 14 dpi with
both vaccines, compared to unvaccinated pigs (Figure 2a).
In general, the PigMAP levels at 12 dpi were decreased by
CP7_E2alf vaccination, as compared to the infected group
without vaccination (p < 0.01). Likewise, the production of
infection-induced IFN-α was shortened from 12 to 7 dpi
and the maximum level at 5 dpi was significantly reduced
with both vaccines (p < 0.02) (Figure 2b). No significant
modulation of TNF-α production was obtained post-
challenge between vaccinated and unvaccinated animals.
A slightly lower TNF-α level was measured on 14 dpi in
CP7_E2alf vaccinated pigs as compared to unvaccinated
pigs (Figure 2c). Due to the high variability in TNF-α
levels between groups at the beginning of the experiment,
bias was avoided by also applying the Wilcoxon test to sta-
tistically compare each after-treatment value with the
before-treatment (0 dpv) value. The duration of high levels
of TNF-α was significantly reduced in both vaccinated
Table 1 CSFV genome detection using real time RT-PCR and virus titration in blood from infected groups
Group Pig
no
2 5 7 9 12 14 16 20 23 27 Dpv
0 3 5 7 10 12 14 18 21 25 Dpi
infected 3906 -/NI +/1.7 +/3.5 +/4.7 +/5.7 +/6.5 +/5.7 +/5.9 +/6.1 na
3920 -/NI +/1.7 +/3.5 +/4.3 +/NI +/NI +/NI +/NI +/NI +/NI
3912 -/NI +/2.1 +/3.1 +/3.3 +/NI +/NI +/NI +/NI +/NI +/NI
3934 -/NI +/1.9 +/3.1 +/4.5 +/4.1 +/3.5 +/2.9 +/NI +/NI +/NI
3935 -/NI +/NI +/3.7 +/3.9 +/1.7 +/NI +/NI +/NI +/NI +/NI
CP7_E2alf vacc & chal 3917 -/NI +/NI +/2.9 +/NI +/NI +/NI +/NI +/NI -/NI -/NI
3902 -/NI +/NI +/3.3 +/3.5 +/NI +/NI +/NI +/NI +/NI +/NI
3907 -/NI +/NI +/3.3 +/4.7 +/3.9 +/1.9 +/NI +/NI +/NI +/NI
3931 -/NI +/NI +/2.5 +/NI +/NI +/NI +/NI +/NI +/NI +/NI
3911 -/NI +/NI +/2.9 +/2.9 +/NI +/NI +/NI +/NI +/NI +/NI
C-strain vacc & chal 3918 -/NI +/NI +/2.1 +/NI +/NI +/NI +/NI -/NI -/NI -/NI
3933 -/NI +/NI +/NI +/1.7 +/1.7 +/NI +/NI +/NI -/NI -/NI
3915 -/NI +/NI +/2.9 +/2.7 +/NI +/NI +/NI +/NI +/NI -/NI
3905 -/NI +/NI +/3.3 +/4.1 +/3.7 +/2.7 +/2.3 +/NI +/NI +/NI
3903 -/NI +/1.7 +/3.1 +/3.7 +/1.7 +/NI +/NI +/NI +/NI +/NI
Plus sign indicates positive genome detection (Ct ≤ 45). Minus sign indicates negative genome detection (Ct > 45). Virus titre values are given for 10(x) TCID50/mL
of blood. NI indicates that virus were not isolated. Double positive results are shown in bold type. Double negative results are underlined. na: sample not available
because of death of the pig; CP7 vacc & chal: CP7_E2alf vaccinated and challenged; C vacc & chal: C-strain vaccinated and challenged; dpv: day post-vaccination;
dpi: day post-infection or challenge.
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TGF-β1 levels at 10 dpi (14 ng/mL), which was reduced
by CP7_E2alf vaccination (p = 0.028) (21 ng/mL) and pre-
vented by C-strain vaccination (p = 0.47) (23 ng/mL)
(Figure 2d). These vaccination-induced differences,
compared with the infected group, were significantly
extended at 14 and 18 dpi with the CP7_E2alf vaccine
(p = 0.047) and at 12, 14 and 18 dpi with the C-strain
vaccine (p = 0.047). The increased level of cytokine IL-12
induced by Bas-Rhin infection attained 1698 pg/mL at 7
dpi and remained significant until the end of the experi-
ment (p = 0.016) (Figure 2e). Compared with the infected
group, the CP7_E2alf vaccination did not significantly at-
tenuate infection-induced IL-12 production (p = 0.175) but
differences indicating an earlier return of the IL-12 levels
to normal were apparent at 12 and 14 dpi (p = 0.047). With
C-strain vaccination, the increase in infection-induced IL-
12 production was reduced throughout the experiment
(at 3, 7, 12, 14, 18 and 21 dpi) (p < 0.05). No significant
modulation of IL-6 production in serum was obtained ei-
ther post-infection or post-vaccination (Figure 2f).
The proteins IL-1β, IL-18 and IL-10 were also assessed
by ELISA, but could not be quantified in serum from
any of the pigs, with similar values to the background
values. Although the IL-10 protein was not detected in
serum, expression of the IL-10 gene was measured in
unpurified blood cells using rRT-PCR. Without chal-
lenge, gene expression was similar to that of control pigs
after both types of vaccination (Figure 3). After chal-
lenge at 2 dpv, IL-10 gene expression induced by theBas-Rhin infection was significantly attenuated in both
vaccinated groups, usually at 5 dpi, compared to the un-
vaccinated control group (p = 0.009).
CP7_E2alf vaccine stimulates IgG2 production post-
challenge and differences from the C-strain vaccine were
observed for neutralizing antibodies (NAb) and IgG1
production without challenge.
Without challenge, the C-strain vaccine induced a
higher production of NAb against the Bas-Rhin strain
than the CP7_E2alf vaccine at 14, 23 and 27 dpv
(p > 0.05), with titres of 150 and 31 at 27 dpv (Figure 4).
After challenge at 2 dpv, NAb against the Bas-Rhin
strain were apparent from 12 dpv (10 dpi) in the group
vaccinated with C-strain and from 14 dpv (12 dpi) in the
group vaccinated with CP7_E2 (Figure 4). However the
differences between the vaccinated and unvaccinated
groups were never significant. Both major sub-classes of
IgG anti-CSFV antibodies were detected in the serum.
The IgG1 profile was similar to the above-described
NAb profile, the C-strain vaccine inducing more IgG1
production than the CP7_E2alf vaccine at 20 and 27 dpv
without challenge (p < 0.05) and no difference with
either vaccine post-challenge (Figure 5a). Conversely,
without challenge, no differences between the two vac-
cines were detected (p > 0.05) and post-challenge, both
vaccines induced higher IgG2 levels than the unvacci-
nated group as of 10 dpi (Figure 5b). From these results,
the IgG1:IgG2 ratio was calculated to get information
about the specific immune response potentiation; the
ratio value was lower (Th1) or higher (Th2) than 1.
Figure 2 Cytokine profiles in serum from experimental groups. Levels were quantified using ELISA for (a) PigMAP, (b) IFN-α, (c) TNF-α,
(d) TGF-β1, (e) IL-12 and (f) IL-6. All data are reported as the mean (± SE) of results obtained for the 5 pigs in each group. *p < 0.05 compared
each post-vaccination, post-challenge or post-infection value with the respective control value using the Mann–Whitney test. Dotted line with
white triangles: CP7_E2alf vaccinated group (CP7 vacc); dotted line with white squares: C-strain vaccinated group (C vacc); dotted line with white
circles: control group; full line with black triangles: CP7_E2alf vaccinated and challenged group (CP7 vacc & chal); full line with black squares:
C-strain vaccinated and challenged group (C vacc & chal); full line with black circles: infected group.
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with CP7_E2alf vaccine at all days pv whereas a high ratio
was observed with C-strain vaccine at 23 dpv (ratio = 1.22)
and 27 dpv (ratio = 2.07) (Figure 5c). Post-challenge, a sin-
gle high ratio was obtained at 25 dpi (27 dpv) with theCP7_E2alf vaccine whereas high ratios were obtained with
the C-strain from 18 dpi (20 dpv) onwards (Figure 5c).
We then examined the hypothesis that the CP7_E2alf
vaccine induced a slightly different specific immune res-
ponse by assessing the Th1 and Th2 response-related
Figure 3 IL-10 gene expression assessed using real-time
RT-PCR in blood from experimental groups. The values
presented are the relative expressions calculated from the Ct results
on D3, D5 and D12 post-infection (respectively D5, D7 and D14
post-vaccination), in relation to D0 as described in Materials and
Methods. All data are reported as the mean (± SE) of results
obtained for the 5 pigs in each group. *p < 0.05 compared each
post-vaccination, post-challenge or post-infection value with the
respective control value using the Mann–Whitney test. CP7 vacc:
CP7_E2alf vaccinated; C vacc: C-strain vaccinated; CP7 vacc & chal:
CP7_E2alf vaccinated and challenged; C vacc & chal: C-strain
vaccinated and challenged.
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for these cytokines were below the limits of detection
both in serum by ELISA or in unpurified blood cells by
relative quantitative rRT-PCR (data not shown).
Discussion
This paper demonstrates the similar abilities of the
CP7_E2alf marker vaccine and the C-strain vaccine to
confer partial protection against CSFV challenge with a re-
cent MV isolate, as early as 2 days post-oral immunization.
To our knowledge, this is the first study to investigate the
efficacy of CP7_E2alf vaccine less than one week post-
immunization. An early onset of partial protection against
a challenge with MV strains had already been reported
3 days after intramuscular vaccination with the C-strain
vaccine and complete protection after 5 days [12]. Effec-
tive protection occurred more rapidly when the CP7_E2alf
vaccine was administered by the intramuscular route than
by the oral route [13]. This study also provides further evi-
dence of the early efficacy of live vaccines administered by
oral route and supports that the CP7_E2alf vaccine could
be a good alternative to the C-strain vaccine for the emer-
gency vaccination of pigs or for oral vaccination cam-
paigns in wild boar.
Both vaccines attenuated pathogeny to a similar extent
and before the appearance of NAb. During CSF, viremia isgenerally highly dependent on serum NAb levels. Our
results show that viremia decreased from 7 dpi onwards in
all groups and was already well advanced when NAb was
detected in the serum at 12 dpi (14 dpv). Moreover, the
NAb titers did not differ significantly between vaccinated
and unvaccinated groups, suggesting that other immune
responses, in addition to the NAb response, are involved
in the early onset of partial protection. The immune
responses induced by live vaccines to provide rapid pro-
tection against CSFV infection, and particularly the role of
cytokines, are not fully understood. Our results show that
both live vaccines were able to attenuate some of the cyto-
kine responses induced by CSFV infection. For example,
IFN-α may be involved in CSFV pathogeny and particularly
in lymphopenia induction [16]. In our study, vaccination
was found to reduce serum IFN-α levels post-infection.
Vaccination with DNA vaccine expressing the E2 CSFV
protein has already been shown to attenuate the
IFN-α level [25]. Surprisingly, in the absence of challenge,
a low IFN-α level in relation to the low lymphopenia
observed at 5 dpv, was only induced by C-strain vaccine, in
contrast to the higher attenuation of IFN-α level observed
post-challenge. The transient IFN-α level induced by C-
strain vaccination may stimulate an early host immune re-
sponse to control the production of IFN-α induced by
CSFV infection. During CSFV infection, high levels of
proinflammatory cytokines, suspected to be associated with
the hemorrhage characteristic of the acute form of the dis-
ease, are released by the macrophages [17,26]. Our results
show that TNF-α production was not significantly affected
by vaccination and that neither IL-1 nor IL-6 could be
detected. We previously reported the lower production of
TNF-α induced by infection with a MV strain of CSFV,
and suggested that, in contrast to HV strains, TNF-α may
be of secondary importance with MV strains [27]. Few
hemorrhagic lesions are produced in the sub-acute form of
the disease observed after infection with an MV strain,
which suggests that a lack of proinflammatory cytokines is
released.
Acute phase proteins are good indicators of the inflam-
matory reactions caused by infection, injury or stress and
can be used to monitor animal health. The production of
these proteins in the liver is mainly controlled by proin-
flammatory cytokines [28]. An acute phase response has
already been observed in pigs inoculated with CSFV [29].
In this study, CSFV infection produced an increase in Pig-
MAP, which was attenuated by vaccination. Discrimi-
nation between vaccinated and unvaccinated animals,
based on serum PigMAP levels, has already been demon-
strated after infection with the Aujeszky’s disease virus
[30].
IL-10 levels are increased post-infection and this cyto-
kine is assumed to have a key role in immunosuppression
observed during the course of CSF disease [17,31]. Further
Figure 4 Neutralizing antibody response in serum from
experimental groups. Results of the neutralizing assay against the
Bas-Rhin CSFV strain for vaccinated, challenged and infected groups.
All data are reported as the mean (± SE) of results obtained for the
5 pigs in each group. *p < 0.05 compared each post-challenge value
with the respective post-infection value using the Mann–Whitney
test. Dotted line with white triangles: CP7_E2alf vaccinated group
(CP7 vacc); dotted line with white squares: C-strain vaccinated group
(C vacc); full line with black triangles: CP7_E2alf vaccinated and
challenged group (CP7 vacc & chal); full line with black squares:
C-strain vaccinated and challenged group (C vacc & chal); full line
with black circles: infected group.
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of IL-10 gene expression induced by both vaccines follow-
ing CSFV challenge. Conversely, the production of another
immunosuppressive mediator, TGF-β1, was repressed after
infection with an MV strain, and then prevented by vac-
cination. Our results confirm those of a previous study in-
volving microarray analysis that showed that TGF-β was
down-regulated as early as 1 dpi in PBMC isolated from
pigs infected with an HV strain [32]. TGF-β controls
inflammation and auto-aggressive immune reactions by
CD4+CD25+ regulatory T cell activation [33]. The
impaired TGF-β1 repression observed in CSFV infection
post-vaccination suggests that this effect may also be
related to maintenance of the inflammatory condition and
high levels of cytokines. Interestingly, the levels of IL-12
were enhanced in response to CSFV infection and then
attenuated by the vaccination. A relationship was observed
between the severity of clinical signs and the IL-12 levels,
as illustrated by the one infected pig which displayed a
continual increase in IL-12 levels until death. IL-12 isproduced by dendritic cells in the blood and spleen after
CSFV infection [17] and co-delivery of IL-12 with a DNA
vaccine reduces both the NAb titres and protection
against a CSFV challenge [34]. Our results, however, are
the first real element suggesting involvement of IL-12 in
CSFV pathogeny. IL-12 may play a pathogenic role by en-
hancing the chemoattraction of activated macrophages
induced by the CSFV infection thereby promoting virus
replication and leading to high levels of proinflammatory
cytokines [35].
Thus, the observed post-infection modulation of the
responses of cytokines and their attenuation by vaccination
suggest that these changes in cytokine levels are related to
CSFV pathogeny rather than to protection. It would now
be interesting to understand the CSFV-induced mecha-
nisms which generate these cytokine modulations and how
live vaccines interfere with these modulations. One expla-
nation of the interference of vaccines, in relation to patho-
geny attenuation or partial protection, could be that the
vaccine and challenge strains compete for replication sites
in the tonsils. This hypothesis is supported by the longer
delay for isolation of the virus in blood from vaccinated, as
compared to unvaccinated, pigs.
The IL-12 produced by dendritic cells promotes IFN-γ
secretion by the T cells and NK cells. Together IL-12 and
IL-18 play a synergistic role in this activation [36]. How-
ever, no production of IFN-γ or IL-18 was detected in this
study. During infection, IL-10 facilitates immunosuppres-
sion and viral persistence by inhibiting the activity of Th1
and NK cells [37,38]. Thus, the absence of IFN-γ detection
may be due to the enhancement of IL-10 mediated by
CSFV. Previous studies have shown that the C-strain vac-
cine induces IFN-γ production post-vaccination [12,39]. In
our study, the absence of IFN-γ detection was probably
due to poor sensitivity of the assay. The humoral immune
response plays a major role in protection against CSFV. IL-
4 is produced by Th2 cells and stimulates B cell activation
and immunoglobulin-class switching [40] and is considered
as one of the main indicators of antibody-mediated im-
munity. However, IL-4 was not detected in this study even
though high titres of neutralizing antibodies were mea-
sured, thereby confirming that serum may not be the best
biological matrix for IL-4 or IFN-γ assays [41]. Also, in
many other studies the intramuscular route was used and
it may not be possible to detect these cytokines after
immunization by the oral route.
In swine, IFN-γ has been shown to be related to IgG2
production [42] which supports the hypothesis that the
IgG1:IgG2 ratio could provide a suitable indicator of adap-
tive immunity potentiation towards a Th1 or Th2 response,
as in other species. Interestingly, our results showed that
the post-challenge production of CSFV-specific IgG2, but
not IgG1, was enhanced in vaccinated as compared to un-
vaccinated pigs. This suggests that IgG2, and possibly the
Figure 5 CSFV-specific IgG responses with IgG subclass differentiation assessed by ELISA in serum from experimental groups. a) Results
for the IgG1 subclass. (b) Results for the IgG2 subclass. (c) Results for the IgG1:IgG2 ratio. All samples were assessed the same day with positive
and negative controls on each plate in order to check the sensitivity and the reproducibility of the assay. All data are reported as the mean (± SE)
of OD with subtracted blank value, obtained for the 5 pigs in each group. *p < 0.05 compared each post-vaccination, post-challenge or
post-infection value with its respective control value using the Mann–Whitney test. Dotted line with white triangles: CP7_E2alf vaccinated group
(CP7 vacc); dotted line with white squares: C-strain vaccinated group (C vacc); dotted line with white circles: control group; full line with black
triangles: CP7_E2alf vaccinated and challenged group (CP7 vacc & chal); full line with black squares: C-strain vaccinated and challenged group
(C vacc & chal); full line with black circles: infected group.
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http://www.veterinaryresearch.org/content/44/1/9Th1 immune response, have a role in immunity against
CSFV infection. Surprisingly, in relation to the NAb re-
sponse, vaccination with the C-strain and without chal-
lenge seemed to stimulate IgG1 production to a greater
extent than CP7_E2alf vaccination. The high IgG1:IgG2
ratio clarified this predominance of Th2-humoral response
in animals vaccinated with the C-strain vaccine compared
with CP7_E2alf vaccinated animals, which would counter-
balance towards Th1-cellular response. Nevertheless this
possible difference in trend between the vaccines could not
be correlated with the IFN-γ and IL-4 levels, due to non-
detection of these proteins, and therefore remains hypo-
thetical. However, without challenge, the lymphocyte
counts increased earlier in blood after CP7_E2alf vacci-
nation than after C-strain vaccination (from 12 dpv and
20 dpv, respectively), suggesting that stimulation of
lymphocyte proliferation was improved with the CP7_E2alf
vaccine. Further investigations need to be carried out to
identify the lymphocyte sub-populations concerned and to
bring results supporting different specific immune res-
ponses induced by the two vaccines.
To conclude, the similar early onset of partial protec-
tion induced after oral immunization with the marker
vaccine CP7_E2alf demonstrated its powerful potential
as a substitute for the conventional C-strain vaccine.
The interference of both vaccines in the post-CSFV in-
fection responses of cytokines IFN-α, PigMAP, TGF-β1,
IL-12 and IL-10 supports that the production of these cyto-
kines is related to CSFV pathogeny. We also observed that
CSFV-specific IgG2 production was enhanced by both vac-
cines, suggesting that the Th1-immune response may have
a role in protection against CSFV infection. Differences be-
tween the C-strain and CP7_E2alf vaccines, with regards to
the balance of induced adaptive immune responses, are
hypothesized but require further investigation.
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